SkinBioTherapeutics PLC (SBTX) — Financial Flexibility Index
SkinBioTherapeutics PLC (SBTX) has a Financial Flexibility Index of -0.18x as of June 2025. Free cash flow of GBX-491.17K (operating CF GBX-494.84K minus capex GBX3.66K) represents 0% of total liabilities (GBX2.71 Million). Check SkinBioTherapeutics PLC (SBTX) tangible equity ratio to evaluate the tangible quality of the company's equity base.
Financial Flexibility Index
Free Cash Flow
Total Liabilities
Capital Expenditures
SkinBioTherapeutics PLC Financial Flexibility Index (2016–2025)
Historical Financial Flexibility Index trend for SkinBioTherapeutics PLC across 10 annual periods. For the full cash flow conversion analysis, see SkinBioTherapeutics PLC (SBTX) cash flow conversion.
Annual Financial Flexibility Index for SkinBioTherapeutics PLC (2016–2025)
Year-by-year free cash flow to debt coverage for SkinBioTherapeutics PLC. Explore SkinBioTherapeutics PLC (SBTX) debt coverage ratio to assess how comfortably operating cash covers total debt obligations.
| Year | Flexibility Index | Free Cash Flow (GBX) | Operating CF | Total Liabilities | YoY Change |
|---|---|---|---|---|---|
| 2025 | -0.48x | GBX-1.29 Million | GBX-1.30 Million | GBX2.71 Million | ▲ +57.6% |
| 2024 | -1.13x | GBX-2.53 Million | GBX-2.73 Million | GBX2.25 Million | ▲ +72.8% |
| 2023 | -4.14x | GBX-2.48 Million | GBX-2.65 Million | GBX599.34K | ▲ +2.1% |
| 2022 | -4.23x | GBX-2.58 Million | GBX-2.67 Million | GBX609.61K | ▼ -52.2% |
| 2021 | -2.78x | GBX-1.44 Million | GBX-1.56 Million | GBX519.67K | ▼ -3.4% |
| 2020 | -2.69x | GBX-818.47K | GBX-892.14K | GBX304.83K | ▲ +77.0% |
| 2019 | -11.69x | GBX-1.42 Million | GBX-1.43 Million | GBX121.33K | ▼ -310.9% |
| 2018 | -2.85x | GBX-595.49K | GBX-667.75K | GBX209.29K | ▲ +36.4% |
| 2017 | -4.47x | GBX-530.50K | GBX-609.70K | GBX118.66K | ▼ -211.4% |
| 2016 | 4.01x | GBX135.05K | GBX-1.17K | GBX33.64K | — |